We have been appointed by the Botswana Vaccine Institute (BVI) to supervise the creation of a state-of-the-art, cGMP-compliant veterinary vaccine manufacturing unit in Gaborone, Botswana. This project, set to be operational by 2026, will enhance BVI's capacity and quality of veterinary vaccines, meeting stringent global standards and expanding their market reach.
We are proud to announce that we have been honoured with the prestigious 'Start-up 50: The Trailblazers Award' from Dun & Bradstreet at the LEAP India Startup Summit 2024. This recognition highlights our commitment to innovation, quality, and sustainable growth in the biotech sector. Our self-funded, cash-positive business model, focused on prevention, detection, and treatment of diseases through vaccines, diagnostics, and novel biotherapeutics, has set us apart in the global market.
We break ground for their facility, the ‘Global Collaborative Centre for Medical Countermeasures’ (GCMC), a pivotal advancement in global health security and pandemic preparedness. Recognized at the 2nd World Local Production Forum in the Hague recently, GCMC is in alignment with global health initiatives and our own ‘National Biotechnology Development Strategy’ of India.
We have launched Euvichol-Plus, the world’s first oral cholera vaccine in an LDPE unidose pack, in collaboration with Eubiologics Co., Ltd. This WHO-prequalified vaccine enhances accessibility and safety, supporting the fight against cholera and aligning with the WHO’s goal to end cholera by 2030.
We have entered into a strategic collaboration with Reagent IVD Resources Pvt. Ltd. (RIVDR), a Jaipur-based diagnostics-focused start-up, for the development and manufacturing of a comprehensive range of diagnostics. The portfolio would encompass human as well as veterinary segments for global supplies.
We have achieved promising results from a preliminary study of CoviTech™, its recombinant subunit SARS-CoV-2 vaccine. Developed using the yeast Pichia pastoris platform, the vaccine shows potential as a safe, effective, and affordable option for developing countries, addressing key challenges in vaccine design and production scalability.
© 2023 TechInvention. Developed by Scivision Solutions Pvt. Ltd.